NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Chardan, a global
investment bank, announced that the firm is acting as lead manager
in the follow-on offering for Krystal Biotech, Inc. (NASDAQ: KRYS),
a gene therapy company dedicated to developing and commercializing
novel treatments for patients suffering from dermatological
diseases. The underwritten public offering is valued at
$60 million of Krystal Biotech's
common stock.
The capital raised will be used for various activities,
including advancing clinical trials, research, manufacturing
practices and working capital.
Chardan has participated in advisory and capital raising
transactions totaling more than $2
billion in 2018.
About Chardan
Chardan is an independent global investment bank specializing in
healthcare, SPACs and emerging growth companies. Our range of
services include capital raising, merger and acquisition advisory,
strategic advisory, equity research, corporate access and
institutional trading. Headquartered in New York City, Chardan is a registered
broker-dealer with the U.S. Securities and Exchange Commission and
is a member of the following: FINRA, SIPC, NASDAQ and the NYSE
Arca, Inc.
Learn more about Chardan: www.chardan.com
Media Contact:
Emily
Levine, Chardan
elevine@chardan.com
(646) 465-9018
Tom Rozycki, Prosek Partners
trozycki@prosek.com
(646) 503-5657
View original
content:http://www.prnewswire.com/news-releases/chardan-serves-as-lead-manager-for-krystal-biotech-300735480.html
SOURCE Chardan Capital Markets, LLC